To test the results of Aurora B inhibition in-vivo, we studied the drug-target effects using whole tumor lysates probed for Histone H3 Serine 10 phosphorylation and Aurora B autophosphorylation after administering 25 mg/kg/day of inhibitor subcutaneously for 5 days (Fig. 6A). This evidence concerns the gene AURKB and neoplasm.